|
Sanchez-Villalobos JM, Serna-Berna A, Salinas-Ramos J, Escolar-Perez PP, Luengo-Gil G, Andreu-Galvez M, Martinez-Alonso E, Alcaraz M. Safety and Effectiveness of Volumetric Modulated Arc Therapy-Based Stereotactic Radiosurgery for Posterior Fossa Brain Metastases: A Single-Centre Experience. J Clin Med. 2025 Dec 2;14(23):8540. doi: 10.3390/jcm14238540. PubMed PMID: 41375843.
AÑO: 2025; IF: 2.9
|
41375843
|
Alburquerque-Gonzalez B, Montoro-Garcia S, Bernabe-Garcia A, Bernabe-Garcia M, Campioni-Rodrigues P, Rodriguez-Martinez A, Luque I, Salo T, Perez-Garrido A, Perez-Sanchez H, Cayuela ML, Luengo-Gil G, Luchinat E, Postigo-Corrales F, Staderini T, Nicolas FJ, Conesa-Zamora P. Monastrol suppresses invasion and metastasis in human colorectal cancer cells by targeting fascin independent of kinesin-Eg5 pathway. Biomed Pharmacother. 2024 Jun;175:116785. doi: 10.1016/j.biopha.2024.116785. Epub 2024 May 22. Erratum In: Biomed Pharmacother. 2024 Oct;179:117411. doi: 10.1016/j.biopha.2024.117411. PubMed PMID: 38781869.
AÑO: 2024; IF: 7.5
|
|
Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.
AÑO: 2023; IF: 3.5
|
|
Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.
AÑO: 2023; IF: 3.9
|
|
Luengo-Gil G, Conesa-Zamora P. Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response. Glob Chall. 2021 Dec 16;6(3):2100051. doi: 10.1002/gch2.202100051. eCollection 2022 Mar. PubMed PMID: 35284089; PubMed Central PMCID: PMC8902290.
AÑO: 2022; IF: 5.135
|